Republicans are aiming for major reductions in federal spending, and Medicaid seems a likely target. But the politics of ...

Qfitlia (fitusiran) is the first therapy for both hemophilia A or B, with or without inhibitors, available in the United ...

The end of federal diversity, equity and inclusion programs in the federal government may have a ripple effect on social ...

The CEOs of CVS Health and UnitedHealth Group praised pharmacy benefit managers and promised transparency during investor ...

One particular application of AI on the rise at City of Hope is the development of a large language model (LLM) made ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Researchers found that use of immunosuppressive medication was a strong protective factor, associated with a 60% reduction in ...

Lexeo Therapeutics’ gene therapy provides a healthy version of the frataxin gene, which is critical for energy production in ...

A new article argues dystrophin immunogenicity is an under-examined issue in the treatment of Duchenne muscular dystrophy.

Current observations and foresight into the world of biosimilars, GLP-1s, PBM and payer trends, according to Jeff Casberg, MS ...

Bkemv is being offered at 10% off Soliris, and Epysqli is offered at 30% below Soliris. Both biosimilars treat several of the ...

Eric Cannon, PharmD, FAMCP, discusses how precision medicine advancements and biomarker development can enable targeted ...